Business Context and Reporting Period
This Form 8-K is a current report filed by LeMaitre Vascular, Inc. on July 7, 2017, covering events occurring on July 1, 2017. The filing addresses the resignation of a principal officer and provides preliminary unaudited sales guidance for the second quarter of 2017.
Key Financial Metrics
The filing does not provide historical revenue, profit, cash flow, margin, debt, or liquidity figures. It contains only preliminary sales guidance for the current quarter.
- Q2 2017 Preliminary Sales Guidance: $25.4 million to $25.7 million.
- Status: Unaudited and subject to adjustment.
Material Changes
Executive Departure: Michael T. Wijas, Vice President of Sales for The Americas, notified the Company of his resignation, effective July 7, 2017. The Company has initiated a search for a replacement. During the interim, the North American sales management team will report directly to George W. LeMaitre, Chairman and Chief Executive Officer.
Guidance, Outlook, and Risks
Management expects Q2 2017 sales to fall within the $25.4 million to $25.7 million range. The filing includes standard forward-looking statement disclaimers, noting that actual results may differ due to risks and uncertainties. These risks are detailed in the "Risk Factors" section of the Company's most recent Annual Report on Form 10-K and subsequent SEC filings.
Investor Verification Checklist
- Verify the final audited Q2 2017 sales figures once the official earnings release is issued.
- Monitor the timeline and outcome of the search for a replacement for the Vice President of Sales, The Americas.
- Review the Company's most recent Form 10-K for detailed risk factors affecting future performance.
- Confirm the reporting structure for North American sales under the interim leadership of the CEO.